Jin Rong Jie·2025-08-12 04:08Core Viewpoint - Fosun Pharma (02196.HK) experienced a significant stock price increase following the announcement of a licensing agreement with Expedition for the development and commercialization of the investigational product XH-S004 outside of China and Hong Kong [1] Group 1: Licensing Agreement Details - Fosun Pharma's subsidiary granted Expedition rights to develop, produce, and commercialize XH-S004 in a global scope excluding mainland China and Hong Kong [1] - Expedition will pay up to $120 million in non-refundable upfront payments and milestone payments related to development and regulatory achievements [1] - Additionally, based on annual net sales performance of the licensed product, Expedition may pay up to $525 million in sales milestone payments to Fosun Pharma [1] Group 2: Product Information - XH-S004 is a small molecule oral DPP-1 inhibitor with potential indications including non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease (COPD) [1] - The product is currently in Phase II clinical trials for treating non-cystic fibrosis bronchiectasis and in Phase Ib clinical trials for COPD within mainland China [1]